Furthermore, it has been revealed that all-trans-retinoic acid (ATRA) could be a candidate drug for the treatment of gastric cancer patients with high SLC2A1 expression and resistance to conventional chemotherapy (Min et al., 2021). Here, SLC2A1 is linked to gastric cancer.